Tags

Type your tag names separated by a space and hit enter

Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
Eur J Health Econ. 2008 Feb; 9(1):7-15.EJ

Abstract

In Germany, the seven-valent conjugate vaccine Prevenar is recommended for use in children at high risk of pneumococcal disease. Recent data suggest that giving conjugate vaccine to all children may lead to a decline in pneumococcal disease in unvaccinated adults, a phenomenon known as herd immunity. This analysis evaluated the cost and economic consequences in Germany of vaccinating (1) children at high risk, (2) all children when considering only benefits for vaccinated individuals and (3) all children when also considering herd immunity benefits. Costs in the model included vaccination, management of meningitis, bacteraemia, pneumonia and acute otitis media, insurance payments to parents and the costs of care for long-term disabilities. The model estimated that the cost-effectiveness of vaccination would be 38,222 euros per life year gained in children at high risk and 100,636 euros per life year gained in all children when not considering herd immunity. When considering herd immunity effects, the model estimated that offering vaccination for all children would reduce adult deaths by 3,027 per year, and vaccination would be broadly cost neutral. The findings are sensitive to the effect of conjugate vaccine on the rates of pneumonia and invasive disease in the elderly. If the herd immunity effect of conjugate vaccination in Germany is similar to that observed elsewhere, offering vaccine to all children will be more attractive than the current policy of restricting vaccination to children at high risk of pneumococcal disease.

Authors+Show Affiliations

Fourth Hurdle Consulting Ltd, London, WC1V 6PL, UK. adamlloyd@fourthhurdle.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17333089

Citation

Lloyd, Adam, et al. "Cost-effectiveness of Heptavalent Conjugate Pneumococcal Vaccine (Prevenar) in Germany: Considering a High-risk Population and Herd Immunity Effects." The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care, vol. 9, no. 1, 2008, pp. 7-15.
Lloyd A, Patel N, Scott DA, et al. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects. Eur J Health Econ. 2008;9(1):7-15.
Lloyd, A., Patel, N., Scott, D. A., Runge, C., Claes, C., & Rose, M. (2008). Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects. The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care, 9(1), 7-15.
Lloyd A, et al. Cost-effectiveness of Heptavalent Conjugate Pneumococcal Vaccine (Prevenar) in Germany: Considering a High-risk Population and Herd Immunity Effects. Eur J Health Econ. 2008;9(1):7-15. PubMed PMID: 17333089.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects. AU - Lloyd,Adam, AU - Patel,Nishma, AU - Scott,David A, AU - Runge,Claus, AU - Claes,Christa, AU - Rose,Markus, Y1 - 2007/03/02/ PY - 2005/12/05/received PY - 2006/09/21/accepted PY - 2007/3/3/pubmed PY - 2008/5/3/medline PY - 2007/3/3/entrez SP - 7 EP - 15 JF - The European journal of health economics : HEPAC : health economics in prevention and care JO - Eur J Health Econ VL - 9 IS - 1 N2 - In Germany, the seven-valent conjugate vaccine Prevenar is recommended for use in children at high risk of pneumococcal disease. Recent data suggest that giving conjugate vaccine to all children may lead to a decline in pneumococcal disease in unvaccinated adults, a phenomenon known as herd immunity. This analysis evaluated the cost and economic consequences in Germany of vaccinating (1) children at high risk, (2) all children when considering only benefits for vaccinated individuals and (3) all children when also considering herd immunity benefits. Costs in the model included vaccination, management of meningitis, bacteraemia, pneumonia and acute otitis media, insurance payments to parents and the costs of care for long-term disabilities. The model estimated that the cost-effectiveness of vaccination would be 38,222 euros per life year gained in children at high risk and 100,636 euros per life year gained in all children when not considering herd immunity. When considering herd immunity effects, the model estimated that offering vaccination for all children would reduce adult deaths by 3,027 per year, and vaccination would be broadly cost neutral. The findings are sensitive to the effect of conjugate vaccine on the rates of pneumonia and invasive disease in the elderly. If the herd immunity effect of conjugate vaccination in Germany is similar to that observed elsewhere, offering vaccine to all children will be more attractive than the current policy of restricting vaccination to children at high risk of pneumococcal disease. SN - 1618-7598 UR - https://www.unboundmedicine.com/medline/citation/17333089/Cost_effectiveness_of_heptavalent_conjugate_pneumococcal_vaccine__Prevenar__in_Germany:_considering_a_high_risk_population_and_herd_immunity_effects_ L2 - https://dx.doi.org/10.1007/s10198-006-0013-6 DB - PRIME DP - Unbound Medicine ER -